Redefining how the world approaches, prevents, and heals mental health disorders.
We are a biotechnology company pioneering mental health innovation. We are committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.
LEARN MORE
OUR PERSPECTIVE
Shortcomings of existing therapies
Current standard of care treatments are ineffective for millions worldwide.
Limited Efficacy
Slow onset – Up to 3 months or more for SSRIs to take full effect
Trial and error – Remission with first selected SSRI occurs only 30% of the time
Low response rate – Only 50% respond within 8 weeks and 33% become treatment-resistant
High relapse rate – Estimated that 40-60% of patients with SUD return to active addiction
Side Effects
Addiction – 10-15% of benzodiazepine users become addicted
Sexual dysfunction – 55% of patients on SSRIs experience sexual dysfunction
Weight gain – Depending on the drug, patients on SSRIs gain on average 16-24lbs over 12 months
Sleep – SSRIs interfere with sleep architecture, potentially complicating the sleep of depressed patients
Our unique approach
Compounds with prior evidence in humans
To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.
Enabling platform technologies
First-in-class
Our portfolio includes a number of assets that have the potential to be developed as first-in-class therapeutics. These are programs which include natural products and their derivatives that have not previously been formally developed as drugs, as well as de novo compounds.
Learn more about our approach
OUR MODELWHERE WE’RE HEADED
Our technologies drive efficient drug discovery and improved treatment outcomes.
Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics.
OUR MODELNews & Insights
Press Release
atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer
atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the…
Press Release
ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round
ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the…
News
Gender Disparities and Mental Health Risk Factors
We’re social creatures: We not only desire interaction with others but actually need it. Contact with others — particularly physical contact —…